SCM
ABUS icon

Sterling Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Sterling Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.41K Sell
1,201
-331
-22% -$1.45K ﹤0.01% 2688
2025
Q4 		$7.37K Buy
1,532
+617
+67% +$2.77K ﹤0.01% 2756
2025
Q3 		$4.15K Buy
915
+368
+67% +$1.35K ﹤0.01% 2811
2025
Q2 		$1.69K Buy
547
+223
+69% +$740 ﹤0.01% 2957
2025
Q1 		$1.13K Sell
324
-125
-28% -$417 ﹤0.01% 2776
2024
Q4 		$1.47K Buy
449
+288
+179% +$1.06K ﹤0.01% 2861
2024
Q3 		$620 Buy
+161
New +$618 ﹤0.01% 2772
2015
Q2 		– Sell
-14,263
Closed -$249K – 872
2015
Q1 		$249K Buy
+14,263
New +$292K ﹤0.01% 814

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return